JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB210931

Anti-PD-L1 antibody [ABM4E54]

5

(1 Review)

|

(39 Publications)

Mouse Monoclonal PD-L1 antibody. Suitable for IHC-P, Flow Cyt, WB and reacts with Human samples. Cited in 39 publications. Immunogen corresponding to Recombinant Fragment Protein within Human CD274 aa 1-250.

View Alternative Names

CD274, B7H1, PDCD1L1, PDCD1LG1, PDL1, Programmed cell death 1 ligand 1, PD-L1, PDCD1 ligand 1, Programmed death ligand 1, hPD-L1, B7 homolog 1, B7-H1

4 Images
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD-L1 antibody [ABM4E54] (AB210931)
  • IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD-L1 antibody [ABM4E54] (AB210931)

Immunohistochemical analysis of formalin-fixed paraffin-embedded human Hodgkin's lymphoma tissue, labeling PD-L1 with ab210931 at 5 μg/mL.

Flow Cytometry - Anti-PD-L1 antibody [ABM4E54] (AB210931)
  • Flow Cyt

Supplier Data

Flow Cytometry - Anti-PD-L1 antibody [ABM4E54] (AB210931)

Cell Surface flow cytometry analysis of PD-L1 in PHA treated human PBMC using 1 μg of ab210931. Green represents isotype control; pink represents ab210931 antibody. Goat anti-mouse PE conjugate was used as secondary antibody.

Western blot - Anti-PD-L1 antibody [ABM4E54] (AB210931)
  • WB

Supplier Data

Western blot - Anti-PD-L1 antibody [ABM4E54] (AB210931)

Exposure time : 1 minute in film and 30 seconds in imager.

All lanes:

Western blot - Anti-PD-L1 antibody [ABM4E54] (ab210931) at 2 µg/mL

Lane 1:

A549 lysate at 30 µg

Lane 2:

MCF-7 lysate at 30 µg

Lane 3:

293 lysate at 30 µg

Lane 4:

HCT-116 lysate at 30 µg

Lane 5:

Saos2 lysate at 30 µg

Lane 6:

HeLa lysate at 30 µg

Predicted band size: 33 kDa

false

Western blot - Anti-PD-L1 antibody [ABM4E54] (AB210931)
  • WB

Supplier Data

Western blot - Anti-PD-L1 antibody [ABM4E54] (AB210931)

All lanes:

Western blot - Anti-PD-L1 antibody [ABM4E54] (ab210931) at 0.5 µg/mL

All lanes:

Recombinant protein fragment of Human PD-L1

Predicted band size: 33 kDa

false

Key facts

Host species

Mouse

Clonality

Monoclonal

Clone number

ABM4E54

Isotype

IgG2a

Light chain type

kappa

Carrier free

No

Reacts with

Human

Applications

Flow Cyt, IHC-P, WB

applications

Immunogen

Recombinant Fragment Protein within Human CD274 aa 1-250. The exact immunogen used to generate this antibody is proprietary information.

Q9NZQ7

style
left-column

Alternative Products

Primary Antibodies

AB209960

Alexa Fluor® 647 Anti-PD-L1 antibody [28-8] - Extracellular domain

RabMAb|Recombinant

Immunocytochemistry/ Immunofluorescence - Alexa Fluor® 647 Anti-PD-L1 antibody [28-8] - Extracellular domain (AB209960)

  • 0
  • 0
Primary Antibodies

AB209959

Alexa Fluor® 488 Anti-PD-L1 antibody [28-8]

RabMAb|Recombinant

Flow Cytometry - Alexa Fluor® 488 Anti-PD-L1 antibody [28-8] (AB209959)

  • 5
  • 1
Primary Antibodies

AB213480

Anti-PD-L1 antibody [EPR20529]

RabMAb|Recombinant|KO Validated|20ul selling size

Immunocytochemistry/ Immunofluorescence - Anti-PD-L1 antibody [EPR20529] (AB213480)

  • 5
  • 5
Primary Antibodies

AB213524

Anti-PD-L1 antibody [EPR19759]

BOND RX™ Validated|RabMAb|Recombinant|KO Validated|20ul selling size

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD-L1 antibody [EPR19759] (AB213524)

  • 5
  • 1
Primary Antibodies

AB205921

Anti-PD-L1 antibody [28-8]

BOND RX™ Validated|20ul selling size|Recombinant|KO Validated|Advanced Validation|RabMAb

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD-L1 antibody [28-8] (AB205921)

  • 4
  • 15
Primary Antibodies

AB228415

Anti-PD-L1 antibody [73-10]

BOND RX™ Validated|KO Validated|RabMAb|Recombinant

Immunohistochemistry (Frozen sections) - Anti-PD-L1 antibody [73-10] (AB228415)

  • 5
  • 1
Primary Antibodies

AB274896

Alexa Fluor® 555 Anti-PD-L1 antibody [73-10]

BOND RX™ Validated|RabMAb|Recombinant|Trial Size

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Alexa Fluor® 555 Anti-PD-L1 antibody [73-10] (AB274896)

  • 4
  • 1
Primary Antibodies

AB228462

Anti-PD-L1 antibody [SP142] - C-terminal

BOND RX™ Validated|20ul selling size|RabMAb|Advanced Validation|Recombinant

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD-L1 antibody [SP142] - C-terminal (AB228462)

  • 5
  • 2

Complementary Products

Assay Kits

AB277712

Human PD-L1 ELISA Kit [28-8]

Recombinant|SimpleStep

ELISA - Human PD-L1 ELISA Kit [28-8] (AB277712)

  • 0
  • 0
Primary Antibodies

AB52587

Anti-PD1 antibody [NAT105]

BOND RX™ Validated|Recombinant

Immunohistochemistry (Frozen sections) - Anti-PD1 antibody [NAT105] (AB52587)

  • 5
  • 9
Secondary Antibodies

AB150077

Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488)

Immunocytochemistry/ Immunofluorescence - Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (AB150077)

  • 5
  • 20
Primary Antibodies

AB9485

Anti-GAPDH antibody - Loading Control

BOND RX™ Validated|Lab Essentials

Immunocytochemistry/ Immunofluorescence - Anti-GAPDH antibody - Loading Control (AB9485)

  • 5
  • 88
Primary Antibodies

AB15580

Anti-Ki67 antibody

BOND RX™ Validated|KO Validated

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Ki67 antibody (AB15580)

  • 5
  • 230
style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"}, "FlowCyt" : {"fullname" : "Flow Cytometry", "shortname":"Flow Cyt"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "5 µg/mL", "IHCP-species-notes": "<p></p> Perform heat-mediated antigen retrieval before commencing with IHC staining protocol.", "FlowCyt-species-checked": "testedAndGuaranteed", "FlowCyt-species-dilution-info": "1-2 µg/mL", "FlowCyt-species-notes": "<p></p>", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "0.5 µg/mL", "WB-species-notes": "<p></p>" } } }
style
left-column
style
left-column

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein G
Storage buffer
Preservative: 0.05% Sodium azide Constituents: PBS, 0.05% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

PD-L1 also known as Programmed Death-Ligand 1 or CD274 is a protein involved in immune modulation. Mechanically PD-L1 interacts with its receptors particularly PD-1 to regulate cellular immune responses. This transmembrane protein has a calculated molecular weight of approximately 33 kDa. PD-L1 is expressed on various cell types including tumor cells and immune cells such as dendritic cells macrophages and B cells. Its expression is often upregulated in response to inflammatory cytokines.
Biological function summary

PD-L1 plays a central role in immune evasion mechanisms utilized by tumors. It is not part of a larger protein complex but directly interacts with PD-1 and CD80. When PD-L1 binds to PD-1 it sends inhibitory signals leading to decreased T cell activation and proliferation allowing cancer cells to avoid immune destruction. PD-L1 expression provides a mechanism for tumors to suppress immune surveillance facilitating tumor progression.

Pathways

PD-L1 is integral to the immune checkpoint pathway which is an important regulator of immune response. The interaction between PD-L1 and PD-1 provides a mechanism for immune tolerance which is part of the broader adaptive immune system pathway. PD-L1 is related to other immune checkpoint proteins such as CTLA-4 in its function to limit autoreactivity and promote immune homeostasis.

PD-L1 is most associated with cancer particularly in tumors such as melanoma and non-small cell lung cancer. PD-L1 expression on tumor cells often correlates with poor prognosis. PD-L1 directly interacts with PD-1 in these cancers a target for immunotherapies such as checkpoint inhibitors which aim to block this interaction and restore immune activity against tumors. PD-L1 involvement extends to autoimmune disorders where altered expression can impact tolerance and lead to immune-related tissue damage.
style
left-column
style
left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:
style
left-column

Target data

Plays a critical role in induction and maintenance of immune tolerance to self (PubMed : 11015443, PubMed : 28813410, PubMed : 28813417, PubMed : 31399419). As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed : 11015443, PubMed : 28813410, PubMed : 28813417, PubMed : 36727298). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed : 10581077). Can also act as a transcription coactivator : in response to hypoxia, translocates into the nucleus via its interaction with phosphorylated STAT3 and promotes transcription of GSDMC, leading to pyroptosis (PubMed : 32929201).. The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed : 28813410, PubMed : 28813417). The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function (By similarity). The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (By similarity).
See full target information CD274
style
left-column

Publications (39)

Recent publications for all applications. Explore the full list and refine your search

Molecules (Basel, Switzerland) 30: PubMed40807274

2025

Targeting RARγ Decreases Immunosuppressive Macrophage Polarization and Reduces Tumor Growth.

Applications

Unspecified application

Species

Unspecified reactive species

Jihyeon Park,Jisun Oh,Sang-Hyun Min,Ji Hoon Yu,Jong-Sup Bae,Hui-Jeon Jeon

Journal of assisted reproduction and genetics 42:611-625 PubMed39663282

2024

Upregulation of PD-L1 contributes to improving the apoptosis of granulosa cells via the PI3K/AKT pathway in PCOS.

Applications

Unspecified application

Species

Unspecified reactive species

Rui Han,Yuejie Zhu,Xiaoting Zhang,Xiaoran Liu,Yan Xia,Erdengqieqieke Ye,Xiaolin La,Jianbing Ding

Molecular diagnosis & therapy 29:103-115 PubMed39485665

2024

Targeted Therapy in Salivary Gland Cancer: Prevalence of a Selected Panel of Actionable Molecular Alterations in a German Tertiary Referral Center Patient Cohort.

Applications

Unspecified application

Species

Unspecified reactive species

Maximilian Linxweiler,Silke Wemmert,Felix Leon Braun,Sandrina Körner,Lukas Alexander Brust,Moritz Knebel,Gilbert Georg Klamminger,Mathias Wagner,Luc G T Morris,Jan Philipp Kühn

Cancers 16: PubMed39199657

2024

Development of Ex Vivo Analysis for Examining Cell Composition, Immunological Landscape, Tumor and Immune Related Markers in Non-Small-Cell Lung Cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Elena G Ufimtseva,Margarita S Gileva,Ruslan V Kostenko,Vadim V Kozlov,Lyudmila F Gulyaeva

Scientific reports 13:18476 PubMed37898690

2023

Recombinant immunotoxin induces tumor intrinsic STING signaling against head and neck squamous cell carcinoma.

Applications

Unspecified application

Species

Unspecified reactive species

Guiqin Xie,Liang Shan,Cuicui Yang,Yuanyi Liu,Xiaowu Pang,Shaolei Teng,Tzyy-Choou Wu,Xinbin Gu

BMC cancer 23:971 PubMed37828429

2023

Cholinergic signaling influences the expression of immune checkpoint inhibitors, PD-L1 and PD-L2, and tumor hallmarks in human colorectal cancer tissues and cell lines.

Applications

Unspecified application

Species

Unspecified reactive species

Nyanbol Kuol,Janusz Godlewski,Zbigniew Kmiec,Sara Vogrin,Sarah Fraser,Vasso Apostolopoulos,Kulmira Nurgali

Frontiers in immunology 14:1128244 PubMed37818357

2023

PLEKHA4 is a novel prognostic biomarker that reshapes the tumor microenvironment in lower-grade glioma.

Applications

Unspecified application

Species

Unspecified reactive species

Wenqian Zhi,Ye Wang,Chenyu Jiang,Yuqin Gong,Qiuyan Chen,Xiang Mao,Wensheng Deng,Shasha Zhao

Journal of hepatocellular carcinoma 10:1051-1067 PubMed37449280

2023

Infiltration of a Unique CD8CD274 Cell Subgroup in Hepatocellular Carcinoma is Associated with Poor Clinical Outcomes.

Applications

Unspecified application

Species

Unspecified reactive species

Yong Zhang,Kaisa Cui,Yaoxiang Yang,Bingxin Liu,Minzheng Zhu,Hanqing Chen,Chong Zhao,Youlian Zhou,Yuqiang Nie

Cancers 15: PubMed37444518

2023

MET Receptor Tyrosine Kinase Inhibition Reduces Interferon-Gamma (IFN-γ)-Stimulated PD-L1 Expression through the STAT3 Pathway in Melanoma Cells.

Applications

Unspecified application

Species

Unspecified reactive species

Kyu Young Song,Yong Hwan Han,Heidi Roehrich,Mary E Brown,Carlos Torres-Cabala,Alessio Giubellino

Cancers 15: PubMed37345044

2023

[Zr]-Atezolizumab-PET Imaging Reveals Longitudinal Alterations in PDL1 during Therapy in TNBC Preclinical Models.

Applications

Unspecified application

Species

Unspecified reactive species

Adriana V F Massicano,Patrick N Song,Ameer Mansur,Sharon L White,Anna G Sorace,Suzanne E Lapi
View all publications
style
left-column
style
left-column
style
right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com